LEADER 05348nam 2200649 450 001 9910817344203321 005 20200520144314.0 010 $a0-12-802187-X 035 $a(CKB)3710000000251717 035 $a(EBL)1811527 035 $a(SSID)ssj0001374838 035 $a(PQKBManifestationID)11994564 035 $a(PQKBTitleCode)TC0001374838 035 $a(PQKBWorkID)11326497 035 $a(PQKB)10402985 035 $a(Au-PeEL)EBL1811527 035 $a(CaPaEBR)ebr10950298 035 $a(CaONFJC)MIL649667 035 $a(OCoLC)899273378 035 $a(MiAaPQ)EBC1811527 035 $a(EXLCZ)993710000000251717 100 $a20141018h20152015 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aDesign and manufacture of pharmaceutical tablets /$fReynir Eyjolfsson 210 1$aLondon, England :$cAP,$d2015. 210 4$dİ2015 215 $a1 online resource (68 p.) 300 $aDescription based upon print version of record. 311 $a0-12-802182-9 311 $a1-322-18403-8 320 $aIncludes bibliographical references at the end of each chapters and index. 327 $aCover; Title Page; Copyright Page; Dedication; Contents; Preface; Abbreviations; Chapter One - Introduction; 1.1 - General considerations; 1.2 - Particle sizes; 1.3 - Excipients; 1.3.1 - Ac-Di-Sol SD-711; 1.3.2 - Aerosil 200; 1.3.3 - Avicel PH-102; 1.3.4 - Compactrol; 1.3.5 - Corn starch; 1.3.6 - Di-Tab; 1.3.7 - Eudragit RS PO; 1.3.8 - Magnesium stearate 5712; 1.3.9 - Mannitol 60; 1.3.10 - Methocel K4M Premium; 1.3.11 - Methocel K100M Premium; 1.3.12 - Methocel K100LV Premium; 1.3.13 - Pharmatose 150M; 1.3.14 - Polyplasdone XL-10; 1.3.15 - Povidone; 1.3.16 - Primojel; 1.3.17 - Pruv 327 $a1.3.18 - Sodium bicarbonate1.3.19 - Starch 1500; 1.3.20 - Stearic acid 2236; 1.3.21 - Sterotex K; 1.3.22 - Tablettose 80; 1.3.23 - Talc; 1.4 - Equipment; 1.5 - Mixing of pharmaceutical powders; 1.6 - Design of experiments; 1.6.1 - Introduction to statistical design of experiments - the two-level factorial; 1.6.1.1 - Introduction; 1.6.1.2 - Designed experiments; 1.6.1.3 - Basic considerations; 1.6.1.4 - Two-level factorials; 1.6.1.5 - Two-level fractional factorials; 1.6.2 - Response surface methodology (RSM); 1.6.2.1 - Introduction; 1.6.2.2 - RSM and a sieving process variable study 327 $a1.6.2.3 - RSM investigation of the properties of a three-component tablet formulationReferences; Chapter two - Conventional-Release (CR) Tablets; 2.1 - Low-dose tablet by direct compression (DC); 2.1.1 - Properties of active pharmaceutical ingredient (API); 2.1.2 - Design; 2.1.3 - Manufacturing method; 2.1.4 - Remarks; 2.2 - High-dose tablet by direct compression; 2.2.1 - Properties of active pharmaceutical ingredient; 2.2.2 - Design; 2.2.3 - Manufacturing method; 2.2.4 - Remarks; 2.3 - Low-solubility API, low-dose tablet by wet granulation (WG) 327 $a2.3.1 - Properties of active pharmaceutical ingredient2.3.2 - Design; 2.3.3 - Manufacturing method; 2.3.4 - Remarks; 2.4 - Soluble API, low-dose tablet by wet granulation; 2.4.1 - Properties of active pharmaceutical ingredient; 2.4.2 - Design; 2.4.3 - Manufacturing method; 2.4.4 - Remarks; 2.5 - Low-solubility API, high-dose tablet by wet granulation; 2.5.1 - Properties of active pharmaceutical ingredient; 2.5.2 - Design; 2.5.3 - Manufacturing method; 2.5.4 - Remarks; 2.6 - Soluble API, high-dose tablet by wet granulation; 2.6.1 - Properties of active pharmaceutical ingredient; 2.6.2 - Design 327 $a2.6.3 - Manufacturing method2.6.4 - Remarks; References; Chapter three - Slow-Release (SR) Tablets; 3.1 - Slow-release tablet using a lipophilic release control agent; 3.1.1 - Properties of active pharmaceutical ingredient (API); 3.1.2 - Design; 3.1.3 - Manufacturing method; 3.1.4 - Remarks; 3.2 - Slow-release tablet using Eudragit and Methocel as release control agents; 3.2.1 - Properties of active pharmaceutical ingredient; 3.2.2 - Design; 3.2.3 - Manufacturing method; 3.2.4 - Remarks; 3.3 - Slow-release tablet using a mixture of Methocels as release control agent 327 $a3.3.1 - Properties of active pharmaceutical ingredient 330 $aDesign and Manufacture of Pharmaceutical Tablets offers real world solutions and outcomes of formulation and processing challenges of pharmaceutical tablets. This book includes numerous practical examples related to actual formulations that have been validated and marketed and covers important data in the areas of stability, dissolution, bioavailibity and processing. It provides important background and theoretical information on design and manufacturing and includes a full section dedicated to design experimental methodology and statistics. In addition, this book offers a a general discuss 606 $aDrugs$xDosage forms 606 $aPharmaceutical industry 606 $aTablets (Medicine) 615 0$aDrugs$xDosage forms. 615 0$aPharmaceutical industry. 615 0$aTablets (Medicine) 676 $a615.1 700 $aEyjolfsson$b Reynir$01623468 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910817344203321 996 $aDesign and manufacture of pharmaceutical tablets$93957874 997 $aUNINA